Biotech veterans John Maraganore and Clive Meanwell have teamed to launch Corsera Health, backed by a $50 million initial funding round, focusing on prevention of cardiovascular disease through integrated AI diagnostics and RNA interference therapies. Corsera plans to develop Klotho Health, an AI-driven early risk assessment tool predicting cardiovascular events, paired with a dual-target RNAi drug aimed at PCSK9 and angiotensinogen—key molecules in lipid regulation and blood pressure control. The startup aims to start clinical trials for its drug by year-end, blending precision diagnostics with targeted RNA-based treatment to interdict disease progression. This enterprise embodies a novel, integrated approach to cardiovascular risk management, potentially reshaping prevention strategies.